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Scheme S1. Chemical reaction scheme for the preparation of complex 2. Figure S1 . High resolution ESI mass spectrum (positive mode) of 2. The elemental composition report for the assigned molecular ion peak matches the predicted molecular formula for the potassium salt of 2. 
